دورية أكاديمية
Randomized phase II study of weekly carfilzomib 70 mg/m 2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
| العنوان: | Randomized phase II study of weekly carfilzomib 70 mg/m 2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients |
|---|---|
| المؤلفون: | Puertas, Borja, González Calle, Verónica, Sureda, Anna, Moreno, María José, Oriol, Albert, González, Esther, Rosiñol, Laura, López, Jordi, Escalante, Fernando, Martínez Lopez, Joaquín, Carrillo, Estrella, Clavero, Esther, Ríos Tamayo, Rafael, Rey Bua, Beatriz, González Rodríguez, Ana Pilar, Dourdil, Victoria, Arriba, Felipe de, González, Sonia, Pérez de Oteyza, Jaime, Hernández, Miguel T., García Mateo, Aránzazu, Bargay, Joan, Bladé, Joan, Lahuerta, Juan José, San Miguel, Jesús F., Ocio, Enrique M., Mateos, María Victoria |
| المصدر: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
| بيانات النشر: | Ferrata Storti Foundation (Haematologica) |
| سنة النشر: | 2023 |
| المجموعة: | Dipòsit Digital de la Universitat de Barcelona |
| مصطلحات موضوعية: | Ciclofosfamida, Mieloma múltiple, Cyclophosphamide, Multiple myeloma |
| الوصف: | In this randomized phase II study (GEM-KyCyDex, clinicaltrials gov. Identifier: NCT03336073), the combination of weekly carfilzomib 70 mg/m2, cyclophosphamide and dexamethasone (KCd) was compared to carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM) after 1-3 prior lines (PL). One hundred and ninety-seven patients were included and randomized 1:1 to receive KCd (97 patients) or Kd (100 patients) in 28-day cycles until progressive disease or unacceptable toxicity occurred. Patient median age was 70 years, and the median number of PL was one (range, 1-3). More than 90% of patients had previously been exposed to proteasome inhibitors, approximetely 70% to immunomodulators, and approximetely 50% were refractory to their last line (mainly lenalidomide) in both groups. After a median follow-up of 37 months, median progression-free survival (PFS) was 19.1 and 16.6 months in KCd and Kd, respectively (P=0.577). Of note, in the post hoc analysis of the lenalidomide-refractory population, the addition of cyclophosphamide to Kd resulted in a significant benefit in terms of PFS: 18.4 versus 11.3 months (hazard ratio =1.7, 95% confidence interval: 1.1-2.7; P=0.043). The overall response rate and the percentage of patients who achieved complete response was around 70% and 20% in both groups. The addition of cyclophosphamide to Kd did not result in any safety signal, except for severe infections (7% vs. 2%). In conclusion, the combination of cyclophosphamide with Kd 70 mg/m2 weekly does not improve outcomes as compared with Kd alone in RRMM after 1-3 PL, but a significant benefit in PFS was observed with the triplet combination in the lenalidomide-refractory population. The administration of weekly carfilzomib 70 mg/m2 was safe and convenient, and, overall, the toxicity was manageable in both arms. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | 11 p.; application/pdf |
| اللغة: | English |
| تدمد: | 1592-8721 |
| العلاقة: | Reproducció del document publicat a: https://doi.org/10.3324/haematol.2022.282490Test; Haematologica, 2023, vol. 108, num. 10, p. 2753-2763; https://doi.org/10.3324/haematol.2022.282490Test; http://hdl.handle.net/2445/207683Test |
| الإتاحة: | https://doi.org/10.3324/haematol.2022.282490Test http://hdl.handle.net/2445/207683Test |
| حقوق: | cc by (c) Puertas, Borja et al., 2023 ; http://creativecommons.org/licenses/by/3.0/esTest/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.B04D39D0 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 15928721 |
|---|